
ããªã§ãã¥ãŒã¿ã³ãã®ããã®æ³åŸãå¶å®ãmRNAã¯ã¯ãã³ã®æ³ç圱é¿ïŒ
ãªãŒãŠã§ã«ã·ãã£
2022幎2æ24æ¥
å èšäºã¯ãã¡ãã
ããªã§ã¯çŸåšããã¥ãŒã¿ã³ããéºäŒåæ¹å€è ã®ããã®æ³åŸãå¶å®ãããŠããŸããååœã«ã¯ç¥çµã«é¢ããè«žæš©å©æ³ãååšããããããã«å ããŠããªãç¹æ®ãªæ³åŸã§ããã
ãã®æ°ããæ³åŸãå¶å®ãããçç±ã¯äœã ãããïŒ
ãã®æ³åŸãçãŸããçç±ã¯ãããããè¿ããã¡ã«ä»ã®åœã§ãåãããã«å¶å®ããããšæããŸããããã§ã«ããªãã®æ°ã®äººã ãããã¯ã人éã§ã¯ãªãããã©ã³ã¹ãžã§ããã¯ãªååšã«ãªã£ãŠããããã§ãã
COVIDã¯ã¯ãã³ãå€ç°åæ§ãæã¡ãããã®DNAãå€åãããããšã¯åšç¥ã®äºå®ã§ããããã¯ãã¯ã¯ãã³ã«å«ãŸããRNAã ãã§ãªããPablo Campraå士ããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ç¶ããçºèŠããDNAçµæ¶ã®ããã§ãããã®ã§ããCorona2Inspectã®Mik Andersen
ããã®çµæ¶ã調æ»ããŠãããæè¿ã§ã¯ã©ãã³ã¿ã³ã«ã ããããã®çµæ¶ã "çåœäœÂ "ãçæããä¿¡å·ãéã£ãŠããããšã芳å¯ããŠããŸãã
æ¯æ¥ããã®èšŒæ ã¯å¢ããŠãããç¹ã«ããã¢ã³ã»ãã«ãå士ã説æããããã«ãé»ãç®ãéåžžã«äžæè°ãªèº«äœçç¹åŸŽãæã€èµ€ã¡ãããèªçããŠããŸãã
2021幎ããã³ãã»ãã©ã³ããªãŒãå士ã¯ãmRNAã¯ã¯ãã³ã®åãå ¥ãã¯ã²ãã ã®å€åã䌎ãããã®å®éšè¬ã®æäžãåãã人ã¯äººæš©ã倱ããšäžçã«èŠåããã
ãªãŒãŠã§ã«ã·ãã£ã¯ããã¥ãŒã¿ã³ãã§ããããšãã²ãã ãäœããã®æ¹æ³ã§æ¹å€ãããããšãçç±ã«ã人ã ãä»äºã§å·®å¥ãããããšãé²ãããã«ãããªãçŸåšæã£ãŠãããã®çšã§ãããªããçŸå®ã®æ³åŸã®èŠçŽãè±èªã«ããŠããŸãã
ã©ã³ãã«åç»
ãã¬ãŒã¿ãŒÂ :Â æ²æ³ã«ç¥çµã«é¢ããæš©å©ã远å ããæåã®åœã«ãªã£ãããªã¯ã2022幎2æ16æ¥ã«æ³åŸ21.422ãå ¬è¡šããåŸãä»åºŠã¯ãã¥ãŒã¿ã³ããéºäŒåæ¹å€è ãå·®å¥ããªãäžçåã®åœã«ããªããŸããã
å ·äœçã«ã¯ããã®æ³åŸã§ã¯ã"éºäŒç©è³ªã®çªç¶å€ç°ãæ¹å€ã«çŽé¢ããå Žåã®éçšå·®å¥Â "ãçŠæ¢ããŠããŸãã
ä»ã誰ããçåã«æã£ãŠããã®ã¯ããã®æ³åŸãäœã£ãçç±ã¯äœãªã®ããšããããšã§ãã
ããªã¯äžçã§ãææ°ã®äºé²æ¥çš®åœã§ããããããã®ãããªæ³åŸãå¶å®ãããããšã¯é©ãã«ã¯ããããªããåäœå¶æŽŸã®å»åž«ãã¡ãåœåããèŠåããŠããããã«ããããã®æ¥çš®ç©ã«ã¯ããã²ãã ãå€åãããç§å¯ã®ç©è³ªãæåãå«ãŸããŠããã®ã§ããããã¡ããããã®éºäŒåæ¹å€ã¯éºäŒããã
åœæããã³ãã»ãã©ã³ããªãŒãå»åž«ã¯ããããã®æ¥çš®ãåããè ã¯ãã©ã³ã¹ãã¥ãŒãã³ãšãªãããããã£ãŠè£œè¬äŒç€Ÿã®ææç©ãšãªãããã¯ã人暩ã享åã§ããªããªããšèŠåããŠããã
2013幎ã®è£å€ã§ãç±³åœæé«è£ã人éã®DNAã¯Â "èªç¶ã®ç£ç©Â "ã§ãããããç¹èš±ãååŸããããšã¯ã§ããªããšå€æããããšã¯èšæ¶ã«æ°ããããããããã®å€æ±ºã®æåŸã«ãæé«è£ã¯ãmRNAã¯ã¯ãã³-çŸåšäœ¿çšãããŠãã-ã«ãã£ãŠããã²ãã ãæ¹å€ãããå Žåããã®ã²ãã ã¯ç¹èš±ãååŸããããšãã§ãããšããã
ãšãŸããããªã®æ°æ³ã¯äœã確ç«ããŠããã®ã ãããïŒ
åºå
žã¯ãã¡ãããã£ã¢ãªãªã»ãªãã£ã·ã£ã«ïœDocDroid
ãããªãéçšäž»ããåŽåè
ã®éçšãå¥çŽã®æ°žç¶æ§ãããã¯æŽæ°ããŸãã¯éçšã«ãããæé²ãããã¯ç§»åæ§ãããã®ã²ãã ã«çªç¶å€ç°ãããã¯å€åããªãããšãæ¡ä»¶ã«ããŠã¯ãªããªãã
åŽåè
ã¯ãéºäŒåŠçæ€æ»ãåããããšã«ã€ããŠãèªç±æå¿ã«åºã¥ããååãªèª¬æãåããäžã§åæããããšãã§ããã
ãããã®æ€æ»ãéçšè
ã«ãã£ãŠèŠæ±ãããå Žåãéçšè
ã¯ãã®è²»çšãè² æ
ããªããã°ãªããªãã
ãã®çš®ã®æ€æ»ã宿œããå»çæ©é¢ããã³ç ç©¶æããªãã³ã«ãã®æ
å ±ã«ã¢ã¯ã»ã¹ã§ãã䜿çšè
ã¯ãåŽåè
ã®ãã©ã€ãã·ãŒãä¿è·ããããŒã¿ã®æ§ãããªåãæ±ããä¿èšŒããããã«ãããããå®å
šæªçœ®ãæ¡çšããªããã°ãªããªãã
åŽåè
ã¯åžžã«ãéºäŒåæ€æ»ã®çµæåŸãããæ
å ±ã«ã¢ã¯ã»ã¹ããæš©å©ãæããã
ãã®ãããªæ³åŸãç»å ŽããŠããŸãããããªãã¯ãŸã ãããã®æ¥çš®ç©ãã¯ã¯ãã³ã§ãããšä¿¡ããŠããŸããïŒ
åèåç»
1  ãããšã«ã»ãã¬ã»å士ã人é¡ã®éºäŒåããŒã«ãæ±æãããŠããã
2  ã¯ã¯ãã³æ¥çš®è åã³ãã®åå«ã¯äººéã§ã¯ãªã
ã¢ãªã€ãã»ã©ãå»åž«
åèèšäº
1  mRNAã®æè¡ã䜿ã£ããã®ã¯ã人éã®DNAãæ¹é ããŠã人ããã©ã³ã¹ãã¥ãŒãã³ã«å€ããŠããããšãèãããšãæ¬åœã«æªå€¢ã§ããããšãåããã
2   PCRæ€æ»ã¯ããã®ã¯ããŒã³è£œé ã«é¢ããç¹èš±ã§ããåç©å®éšãç°çš®ééºäŒã瀺ãã
3 ããªã«ããããã¥ãŒã¿ã³ãã®æš©å©ä¿è·æ³ã®æç«ãããªå
åå
¬å®çå®å ±
4   ã玹ä»ã æ²æ³ã§ä¿éããåœãçŸããæ°ãã人暩ãç¥çµã®æš©å©ããšã¯äžäœã©ããªæš©å©ãªã®ãïŒ
ç¥çµã®æš©å©ãæšé²ããã³ãã³ãã¢å€§åŠã®ãããžã§ã¯ãã»NeuroRights Initiativeãæãæžå¿µããŠããã®ã¯ãè³ç¥çµã«é¢ããæè¡ã§ãããã¥ãŒããã¯ãããžãŒã人ã
ã®èªç±ãè
ããçšéã§äœ¿ãããããã«ãªãããšã§ãã